Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Gonem, R. Berair, A. Singapuri, R. Hartley, M. Laurencin, G. Bacher, C. Lu, B. Holzhauer, M. Bourne, V. Mistry, I. Pavord, A. Mansur, A. Wardlaw, S. Siddiqui, R. Kay, C. Brightling (Leicester, Oxford, Birmingham, United Kingdom; Basel, Switzerland; East Hannover, United States Of America). LATE-BREAKING ABSTRACT: Phase 2a randomized placebo-controlled trial of the oral prostaglandin D2 receptor (DP2/ CRTh2) antagonist QAW039 in eosinophilic asthma. Eur Respir J 2014; 44: Suppl. 58, 2908

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Effect of QAW039, an oral prostaglandin D2 receptor (DP2/CRTh2) antagonist, upon bronchial epithelial integrity in treatment-resistant asthma in a randomized, placebo controlled study Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Efficacy and safety of abediterol, a long-acting beta2-adrenergic agonist (LABA); three phase II trials in asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 A double blind randomised placebo controlled trial of the PPAR-gamma agonist pioglitazone in mild asthma Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 An open-label pilot study of memantine, an N-methyl-D-aspartate receptor antagonist in chronic cough Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study Source: International Congress 2014 – Asthma and COPD management Year: 2014 A randomized, double-blind, placebo-controlled of vitamin D3 for Irish children with asthma: Baseline data Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 The effect of Theophylline in patients with allergic rhinitis: A double-blind, randomised, crossover study Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Ketamine versus aminophylline for status asthmatic in children: A randomized, controlled trial Source: International Congress 2014 – Lung disease in neonates and beyond Year: 2014 LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 LATE-BREAKING ABSTRACT: A randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 on moderate persistent asthma Source: Annual Congress 2009 - Novel approaches in asthma Year: 2009 Side effects of the leukotriene receptor antagonists in asthmatic children Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist Source: International Congress 2016 – Asthma management Year: 2016 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial Source: Annual Congress 2013 –Treatment of asthma Year: 2013